KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to -$7.5 million.

  • Adaptive Biotechnologies' Free Cash Flow rose 7250.54% to -$7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$62.9 million, marking a year-over-year increase of 4505.17%. This contributed to the annual value of -$98.9 million for FY2024, which is 4080.03% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Free Cash Flow of -$7.5 million as of Q3 2025, which was up 7250.54% from -$13.1 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Free Cash Flow high stood at -$7.5 million for Q3 2025, and its period low was -$74.1 million during Q1 2021.
  • Moreover, its 5-year median value for Free Cash Flow was -$39.9 million (2024), whereas its average is -$40.6 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Free Cash Flow plummeted by 11431.34% in 2021, and later skyrocketed by 7250.54% in 2025.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Free Cash Flow stood at -$63.1 million in 2021, then soared by 48.37% to -$32.6 million in 2022, then grew by 13.3% to -$28.2 million in 2023, then soared by 55.47% to -$12.6 million in 2024, then soared by 40.05% to -$7.5 million in 2025.
  • Its last three reported values are -$7.5 million in Q3 2025, -$13.1 million for Q2 2025, and -$29.7 million during Q1 2025.